Oxidized ATP inhibits T-cell-mediated autoimmunity

European Journal of Immunology

Volumn 40, Issue 9, 2010, Pages 2401-2408

  Lang, Philipp A ^a   Merkler, Doron ^b   Funkner, Pauline ^c   Shaabani, Namir ^c   Meryk, Andreas ^c   Krings, Caroline ^c   Barthuber, Carmen ^c   Recher, Mike ^d   Brück, Wolfgang ^b   Häussinger, Dieter ^c   Ohashi, Pamela S ^a   Lang, Karl S ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ATP receptors; Diabetes; EAE; LCMV; Oxidized ATP

Indexed keywords

2',3'-DIALDEHYDE ATP; ADENOSINE TRIPHOSPHATE; GAMMA INTERFERON; P2RX7 PROTEIN, MOUSE; PURINERGIC P2 RECEPTOR; PURINERGIC P2X7 RECEPTOR;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; AUTOIMMUNITY; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; DIABETES MELLITUS, TYPE 1; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD; TRANSGENIC MOUSE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, PURINERGIC P2; RECEPTORS, PURINERGIC P2X7; SPINAL CORD;

EID: 77956482552     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.200939838     Document Type: Article

References (45)

1. Pinschewer, D. D., Ochsenbein, A. F., Odermatt, B., Brinkmann, V., Hengartner, H. and Zinkernagel, R. M., FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 2000. 164: 5761-5770.
2. Tedesco-Silva, H., Szakaly, P., Shoker, A., Sommerer, C., Yoshimura, N., Schena, F. P., Cremer, M. et al., FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 2007. 84: 885-892.
3. Kronke, M., Leonard,W. J., Depper, J. M., Arya, S. K.,Wong-Staal, F., Gallo, R. C., Waldmann, T. A. and Greene, W. C., Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc. Natl. Acad. Sci. USA 1984. 81: 5214-5218.
4. Lemster, B., Huang, L. L., Irish, W., Woo, J., Carroll, P. B., Abu-Elmagd, K., Rilo, H. R. et al., Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity 1994. 19: 89-98.
5. Fairbanks, L. D., Bofill, M., Ruckemann, K. and Simmonds, H. A., Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J. Biol. Chem. 1995. 270: 29682-29689.
6. Moreland, L. W., Sewell, K. L., Trentham, D. E., Bucy, R. P., Sullivan, W. F., Schrohenloher, R. E., Shmerling, R. H. et al., Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum. 1995. 38: 1177-1186.
7. Sewell, K. L., Parker, K. C., Woodworth, T. G., Reuben, J., Swartz, W. and Trentham, D. E., DAB486IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum. 1993. 36: 1223-1233.
8. Weinblatt, M. E., Maddison, P. J., Bulpitt, K. J., Hazleman, B. L., Urowitz, M. B., Sturrock, R. D., Coblyn, J. S. et al., CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 1995. 38: 1589-1594.
9. Moreland, L. W., Pratt, P. W., Mayes, M. D., Postlethwaite, A., Weisman, M. H., Schnitzer, T., Lightfoot, R. et al., Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum. 1995. 38: 1581-1588.
10. Murgia, M., Hanau, S., Pizzo, P., Rippa, M. and Di Virgilio, F., Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J. Biol. Chem. 1993. 268: 8199-8203.
11. Baricordi, O. R., Ferrari, D., Melchiorri, L., Chiozzi, P., Hanau, S., Chiari, E., Rubini, M. and Di Virgilio, F., An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 1996. 87: 682-690.
12. Budagian, V., Bulanova, E., Brovko, L., Orinska, Z., Fayad, R., Paus, R. and Bulfone-Paus, S., Signaling through P2X7 receptor in human T cells involves p56lck, MAP kinases, and transcription factors AP-1 and NF-kappa B. J. Biol. Chem. 2003. 278: 1549-1560.
13. Moon, H., Na, H. Y., Chong, K. H. and Kim, T. J., P2X7 receptor-dependent ATP-induced shedding of CD27 in mouse lymphocytes. Immunol. Lett. 2006. 102: 98-105.
14. Chused, T. M., Apasov, S. and Sitkovsky, M., Murine T lymphocytes modulate activity of an ATP-activated P2Z-type purinoceptor during differentiation. J. Immunol. 1996. 157: 1371-1380.
15. Dubyak, G. R., Go it alone no more--P2X7 joins the society of heteromeric ATP-gated receptor channels. Mol. Pharmacol. 2007. 72: 1402-1405.
16. Suadicani, S. O., Brosnan, C. F. and Scemes, E., P2X7 receptors mediate ATP release and amplification of astrocytic intercellular Ca2+ signaling. J. Neurosci. 2006. 26: 1378-1385.
17. Sun, Z., Arendt, C. W., Ellmeier, W., Schaeffer, E. M., Sunshine, M. J., Gandhi, L., Annes, J. et al., PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000. 404: 402-407.
18. Bauer, B., Jenny, M., Fresser, F., Uberall, F. and Baier, G., AKT1/PKBalpha is recruited to lipid rafts and activated downstream of PKC isotypes in CD3-induced T cell signaling. FEBS Lett. 2003. 541: 155-162.
19. Pfeifhofer, C., Kofler, K., Gruber, T., Tabrizi, N. G., Lutz, C., Maly, K., Leitges, M. and Baier, G., Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J. Exp. Med. 2003. 197: 1525-1535.
20. Berg-Brown, N. N., Gronski,M. A., Jones, R. G., Elford, A. R., Deenick, E. K., Odermatt, B., Littman, D. R. and Ohashi, P. S., PKCtheta signals activation versus tolerance in vivo. J. Exp. Med. 2004. 199: 743-752.
21. Hermann-Kleiter, N., Thuille, N., Pfeifhofer, C., Gruber, T., Schafer, M., Zitt, C., Hatzelmann, A. et al., PKCtheta and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes. Blood 2006. 107: 4841-4848.
22. Isakov, N. and Altman, A., Protein kinase C(theta) in T cell activation. Annu. Rev. Immunol. 2002. 20: 761-794.
23. Liu, J. O., The yins of T cell activation. Sci STKE 2005. 2005: re1.
24. Smith-Garvin, J. E., Koretzky, G. A. and Jordan, M. S., T cell activation. Annu. Rev. Immunol. 2009. 27: 591-619.
25. Marsland, B. J. and Kopf, M., T-cell fate and function: PKC-theta and beyond. Trends Immunol. 2008. 29: 179-185.
26. Marsland, B. J., Nembrini, C., Schmitz, N., Abel, B., Krautwald, S., Bachmann, M. F. and Kopf, M., Innate signals compensate for the absence of PKC-theta during in vivo CD8(+) T cell effector and memory responses. Proc. Natl. Acad. Sci. USA 2005. 102: 14374-14379.
27. Marsland, B. J., Soos, T. J., Spath, G., Littman, D. R. and Kopf, M., Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J. Exp. Med. 2004. 200: 181-189.
28. Moayeri, M.,Wickliffe, K. E.,Wiggins, J. F. and Leppla, S. H., Oxidized ATP protection against anthrax lethal toxin. Infect. Immun. 2006. 74: 3707-3714.
29. Ohashi, P. S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C. T., Odermatt, B., Malissen, B. et al., Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991. 65: 305-317.
30. von Herrath, M. and Nepom, G. T., Remodeling rodent models to mimic human type 1 diabetes. Eur. J. Immunol. 2009. 39: 2049-2054.
31. Millar, D. G., Garza, K. M., Odermatt, B., Elford, A. R., Ono, N., Li, Z. and Ohashi, P. S., Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat. Med. 2003. 9: 1469-1476.
32. Lang, P. A., Cervantes-Barragan, L., Verschoor, A., Navarini, A. A., Recher, M., Pellegrini, M., Flatz, L. et al., Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. Blood 2009. 113: 1045-1052.
33. Lang, K. S., Recher, M., Junt, T., Navarini, A. A., Harris, N. L., Freigang, S., Odermatt, B. et al., Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 2005. 11: 138-145.
34. Garza, K. M., Chan, S. M., Suri, R., Nguyen, L. T., Odermatt, B., Schoenberger, S. P. and Ohashi, P. S., Role of antigen-presenting cells in mediating tolerance and autoimmunity. J. Exp. Med. 2000. 191: 2021-2027.
35. Kundig, T. M., Schorle, H., Bachmann, M. F., Hengartner, H., Zinkernagel, R. M. and Horak, I., Immune responses in interleukin-2-deficient mice. Science 1993. 262: 1059-1061.
36. Shahinian, A., Pfeffer, K., Lee, K. P., Kundig, T. M., Kishihara, K., Wakeham, A., Kawai, K. et al., Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993. 261: 609-612.
37. Calzascia, T., Pellegrini, M., Hall, H., Sabbagh, L., Ono, N., Elford, A. R., Mak, T. W. and Ohashi, P. S., TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J. Clin. Invest. 2007. 117: 3833-3845.
38. Shigemoto-Mogami, Y., Koizumi, S., Tsuda, M., Ohsawa, K., Kohsaka, S. and Inoue, K., Mechanisms underlying extracellular ATP-evoked interleukin-6 release in mouse microglial cell line, MG-5. J. Neurochem. 2001. 78: 1339-1349.
39. Chiao, C. W., Tostes, R. C. and Webb, R. C., P2X7 receptor activation amplifies lipopolysaccharide-induced vascular hyporeactivity via interleukin-1 beta release. J. Pharmacol. Exp. Ther. 2008. 326: 864-870.
40. Taylor, S. R., Alexander, D. R., Cooper, J. C., Higgins, C. F. and Elliott, J. I., Regulatory T cells are resistant to apoptosis via TCR but not P2X7. J. Immunol. 2007. 178: 3474-3482.
41. North, R. A., Molecular physiology of P2X receptors. Physiol. Rev. 2002. 82: 1013-1067.
42. Hohlfeld, R., Multiple sclerosis: human model for EAE? Eur. J. Immunol. 2009. 39: 2036-2039.
43. Lang, K. S., Georgiev, P., Recher, M., Navarini, A. A., Bergthaler, A., Heikenwalder, M., Harris, N. L. et al., Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J. Clin. Invest. 2006. 116: 2456-2463.
44. Pircher, H., Burki, K., Lang, R., Hengartner, H. and Zinkernagel, R. M., Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989. 342: 559-561.
45. Recher, M., Lang, K. S., Navarini, A., Hunziker, L., Lang, P. A., Fink, K., Freigang, S. et al., Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. Nat. Med. 2007. 13: 1316-1323.LCMV-WE · LFB and PAS.